These four companies are betting big on CBD-based prescription drugs. (STAT Plus)

More reads

• Competitor accuses 23andMe of ‘false negatives’ in cancer-gene testing. (STAT)
• Sanofi investing in gene therapy as R&D focus turns toward rare disease. (BioPharma Dive)
• European medical investor Sofinnova wraps $368 million fund. (Wall Street Journal)
• These four companies are betting big on CBD-based prescription drugs. (STAT Plus)